hired
assist the company in identifying and evaluating various strategies to
enhance stockholder value and leverage AMAG’s core assets – Feraheme®
(ferumoxytol) Injection for Intravenous (IV) use, AMAG’s commercial and
drug development infrastructure, and the company’s balance sheet, which
had more than
“We are committed to enhancing long-term value for AMAG’s stockholders,”
said
AMAG. “The Jefferies team will help us evaluate all means to create
stockholder value and support us in determining the best path forward
for AMAG. We will expeditiously complete this process, which will
include a parallel review of a potential sale of the company and other
strategic merger and acquisition transactions.”
“Since the outcome of this process is yet to be determined, AMAG’s Board
of Directors will continue the search for a new CEO,” stated
Narachi
multiple qualified and actionable CEO candidates. We are committed to
ensuring that a permanent chief executive is named as soon as possible
that has the skill set necessary to drive stockholder value and both
near-term and long-term growth prospects for AMAG. Simultaneously, we
are looking to further strengthen our Board’s capabilities by adding
directors with experience successfully leading or directing specialty
pharmaceutical companies.”
About Feraheme
In
(IV) use is indicated for the treatment of iron deficiency anemia in
adult chronic kidney disease (CKD) patients. Feraheme received
marketing approval from the
30, 2009
thereafter. For full prescribing information and additional product
information, please visit www.feraheme.com.
About
manufactures and markets Feraheme® in
company information, please visit www.amagpharma.com.
Pharmaceuticals, Inc.
Forward-looking Statements
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Terminology such as “may,” “will,”
“should,” “expects,” “intends,” “plans,” “anticipates,” “believes,”
“estimates,” “predicts,” “projects,” “potential,” “continue,” and other
similar terminology or the negative of these terms, are intended to
identify such forward-looking statements, but their absence does not
mean that a particular statement is not forward-looking. Such
forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties that may cause actual results to
differ materially from those anticipated by the forward-looking
statements. These statements are not guarantees of future performance,
involve risks, uncertainties and assumptions that are difficult to
predict, and are based upon assumptions as to future events that may not
prove accurate. Examples of such forward looking statements include: our
statement that our advisors, including
all means to create stockholder value and support us in determining the
best path forward for the company, our statement that we will
expeditiously complete this process and that the process will include a
parallel review of a potential sale of the company and other strategic
merger and acquisition transactions, our statement that we are committed
to ensuring a permanent CEO is named as soon as possible that has the
skill set to drive near and long term growth, and our statement that we
are looking to further strengthen our Board’s capabilities. In any
forward-looking statement in which we express an expectation or belief
as to future results, such expectation or belief is expressed in good
faith and believed to have a reasonable basis, but there can be no
assurance that the statement or expectation or belief will result or be
achieved or accomplished. The following factors, among others, could
cause actual results to differ materially from those described in the
forward-looking statements: the risk that we may not enter into any
sale, merger or other strategic transaction which creates stockholder
value in a timely manner or at all because no such transaction is
available to us or is not available to us on acceptable terms, the risk
that we may not be able to identify and retain qualified CEO and/or
Board candidates or may not be able to do so in a timely manner; and
other economic, business, competitive, and/or regulatory factors
affecting our business generally, including those risks set forth in the
our
Quarterly Report on Form 10-Q for the quarter ended
and in our other periodic reports and filings with the
investors not to place undue reliance on the forward-looking statements
contained herein. All forward-looking statements are based on
information currently available to us on the date hereof, and we
undertake no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date hereof,
except as required by law.
Source:
AMAG Pharmaceuticals Contact:
Amy Sullivan, 617-498-3303
